PFE vs JNJ
Pfizer Inc. vs Johnson & Johnson · Updated Sep 25, 2026
PFE — 11 winsJNJ — 12 wins
Price Performance
PFE +20.49%JNJ +52.53%
Performance
| PFE | JNJ | |
|---|---|---|
| 1 Month | -0.54% | -0.42% |
| 3 Months | +20.05% | +11.07% |
| 6 Months | +4.12% | +13.44% |
| YTD | +14.12% | +31.43% |
| 1 Year | +17.76% | +54.03% |
| 3 Year | -23.33% | +64.81% |
| 5 Year | -17.49% | +82.46% |
Yearly Returns
| YTD | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PFE | +12.9% | -6.4% | -10.8% | -43.8% | -9.4% | +60.4% | -0.8% | -9.4% | +19.8% | +9.8% | +1.6% | +3.0% |
| JNJ | +30.8% | +43.7% | -9.6% | -12.0% | +3.0% | +9.3% | +7.8% | +14.2% | -7.3% | +20.6% | +14.7% | -1.7% |
Valuation
| PFE | JNJ | |
|---|---|---|
| P/E Ratio | 21.69 | 31.44 |
| Forward P/E | 9.08 | 11.17 |
| PEG Ratio | -3.95 | 2.75 |
| P/S Ratio | 2.49 | 6.76 |
| P/B Ratio | 1.75 | 8.02 |
| EV/EBITDA | 13.15 | 20.46 |
Financials
| PFE | JNJ | |
|---|---|---|
| EPS (TTM) | $1.31 | $8.65 |
| Gross Margin | +67.26% | +71.49% |
| Operating Margin | +27.90% | +26.58% |
| Net Margin | +18.60% | +21.76% |
| ROE | +8.31% | +25.92% |
| ROA | +3.61% | +10.47% |
| Debt/Equity | 0.72 | 0.22 |
Growth
| PFE | JNJ | |
|---|---|---|
| Revenue Growth YoY | +5.37% | +9.91% |
| Revenue Growth QoQ | -17.69% | -2.04% |
| EPS Growth YoY | -9.55% | -52.86% |
| EPS Growth QoQ | +262.07% | +1.90% |
Technical
| PFE | JNJ | |
|---|---|---|
| RSI (14) | 64.43 | 56.81 |
| % From 20-Day SMA | +1.39% | +0.97% |
| % From 50-Day SMA | +5.59% | +2.81% |
| % From 200-Day SMA | +7.95% | +13.34% |
| % From 52-Week High | -2.72% | -3.23% |
| % From 52-Week Low | +20.50% | +54.77% |
Analyst Ratings
PFE
Hold(14 analysts)
Strong SellHoldStrong Buy
Price Target
$28.50
+3.58% upside
JNJ
Buy(21 analysts)
Strong SellHoldStrong Buy
Price Target
$286.93
+5.50% upside
Overview
| PFE | JNJ | |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - General | Drug Manufacturers - General |
| Exchange | NYSE | NYSE |
| Market Cap | $157.50B | $651.20B |
| Shares Outstanding | 5.70B | 2.41B |
| Avg Volume (10D) | 34.90M | 6.58M |
| Dividend Yield | 6.22% | 1.95% |
Frequently Asked Questions
Is PFE or JNJ a better buy right now?
Based on 23 comparable metrics, JNJ leads in 12 categories while PFE leads in 11. JNJ has a consensus analyst rating with 21 analysts covering the stock. Neither stock should be purchased based on a single comparison — consider your investment goals and risk tolerance.
Which stock has better performance, PFE or JNJ?
Over the past year, PFE returned +17.76% compared to JNJ's +54.03%. In the short term (1 month), PFE returned -0.54% vs JNJ's -0.42%.
Is PFE or JNJ more expensive?
PFE trades at a P/E of 21.69 compared to JNJ's 31.44. On a price-to-sales basis, PFE trades at 2.49x vs JNJ's 6.76x. Forward P/E: PFE at 9.08 vs JNJ at 11.17.
Which stock has higher growth, PFE or JNJ?
PFE's revenue grew +5.37% year-over-year compared to JNJ's +9.91%. EPS growth: PFE at -9.55% vs JNJ at -52.86%.
Do PFE and JNJ pay dividends?
PFE pays a dividend with a yield of 6.22%. JNJ pays a dividend with a yield of 1.95%.
Which stock do analysts prefer, PFE or JNJ?
PFE has 14 analysts with a target price of $28.50 (+3.58% upside). JNJ has 21 analysts with a target of $286.93 (+5.50% upside).
Data updated daily. All comparisons based on latest available market data. Not investment advice.